Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (364)	9/4/2003 10:33:27 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 523

VR1-receptor AGONIST????? European Conference On Pain Features NeurogesX Symposium On Capsaicin And Neuropathic Pain Examining the Roles of Capsaicin and VR1 Receptor Agonists PRAGUE, Czech Republic--(BUSINESS WIRE)--Sept. 4, 2003--A symposium on neuropathic pain, sponsored by NeurogesX, Inc., was held today at the 4th Congress of the European Federation of IASP Chapters (International Association for the Study of Pain), in Prague, Czech Republic. The symposium, entitled "Neuropathic Pain: Emerging Role of VR1 Receptor Agonists," featured presentations from three scientists studying the roles of capsaicin and VR1 receptor agonists in the treatment of neuropathic pain. The first presentation, "Lessons from Peppers and Peppermints: An Emerging Molecular Logic of Thermosensation," was made by the symposium's chair, David Julius, Ph.D., professor and vice-chair in the Department of Cellular and Molecular Pharmacology at the University of California, San Francisco. Dr. Julius is also a member of NeurogesX's Scientific Advisory Board. Dr. Julius presented the biology of the vanilloid receptor (VR1) in terms of its role in neuropathic pain. The second presentation, "Effect of Capsaicin on Structure and Function of Peripheral Nerve Fibers," was made by Donald Simone, professor of the Department of Oral Sciences, at University of Minnesota, Minneapolis, Minn. Dr. Simone summarized the impact of capsaicin on peripheral nerve fibers. The symposium's third presentation, "Topical High-Concentration Capsaicin: Prospects for Treatment of Peripheral Neuropathic Pain," was made by Nathaniel Katz, M.D., assistant professor of Neurology and Anesthesia at Harvard Medical School, Boston, Mass. Dr. Katz is also a member of NeurogesX's Scientific Advisory Board. Dr. Katz presented previously announced results of Phase II trials of a capsaicin-based dermal patch used to reduce neuropathic pain in patients suffering from postherpetic neuralgia. "Today's symposium is another indication of the growing worldwide interest in VR1 agonists and their role in neuropathic pain," said Wendye Robbins, M.D., vice chairman and founder of NeurogesX. "Targeting these receptors for the treatment of chronic pain has shown promising results in our clinical programs." About NeurogesX NeurogesX (neur-o-GEE-six) is a privately held specialty pharmaceutical company focusing on the development of products for the treatment of nerve signaling disorders. The company's initial products are focused on the treatment of chronic and acute pain. The company's first product, a topical treatment for neuropathic pain has been evaluated in a Phase II randomized double blind trial. Two phase II/ III multi-center clinical trials are currently enrolling patients. The company has raised $30 million in total equity investments since its first funding round in June 2000. Investors include Alta Partners, ARCH Venture Partners, Montreux Equity Partners, Grove Street Advisors Affiliated Fund, TIAA (Teachers Insurance and Annuity Association), Duke University, University of North Carolina and Walden International. For more information about NeurogesX, go to www.neurogesx.com. NeurogesX is a trademark of NeurogesX, Inc. All other trademarks and registered trademarks are those of their respective companies.